Digital Color Doppler Ultrasound System (P60 Series)

This document details the FDA's determination of substantial equivalence for Sonoscape Medical Corp.'s Digital Color Doppler Ultrasound System (P60 Series), a general-purpose ultrasonic imaging device. The system integrates advanced imaging modes, including AI-powered automated measurement tools like S-FetusAI for fetal recognition, with non-clinical safety tests confirming its compliance and operational reliability.

The Sonoscape Medical Corp.'s Digital Color Doppler Ultrasound System (P60 Series) has received a determination of substantial equivalence from the U.S. Food & Drug Administration, enabling its market availability under standard regulatory controls such as annual registration, device listing, and adherence to good manufacturing practices. This general-purpose ultrasonic imaging instrument is designed for a wide array of medical evaluations, encompassing critical areas like fetal, abdominal, pediatric, vascular, and cardiac applications, showcasing its versatility across diverse clinical settings. The P60 Series system integrates comprehensive operating modes, including B-mode, M-mode, various Doppler functionalities (Color, Power, Pulsed Wave, Continuous Wave), 3D/4D imaging, and elastography, providing clinicians with robust diagnostic capabilities. A key advancement is the inclusion of an AI-powered S-FetusAI function, which automates fetal recognition and measurement, alongside other automated measurement tools for areas such as the bladder, breast, and thyroid. Non-clinical safety and performance tests, specifically evaluating the S-FetusAI feature, were conducted to confirm the device's compliance with applicable medical device standards, supporting its reliable and accurate operation.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific clinical data supports the accuracy and reliability of the AI-powered S-FetusAI function compared to traditional manual measurements?; How do the advanced imaging modes (e.g., 3D/4D, elastography) on the P60 Series compare in diagnostic performance to established high-end ultrasound systems?; What are the ongoing post-market surveillance plans for the P60 Series, particularly concerning the performance and potential biases of its AI features in diverse patient populations?; Can Sonoscape provide details on the specific medical device standards and the methodology used for the non-clinical safety and performance tests, especially for the AI components?; What training and support will be provided to clinicians to effectively utilize and interpret the automated measurement tools and advanced imaging features, including the S-FetusAI function?